University of Florida Research Foundation, Incorporated

Gila Therapeutics, Inc.

Andres Acosta

Sergei Zolotukhin

Beth Anne-Szkudlarek Brown

Sean M Crosson

Seth Currlin

Cedrick Shawn Dotson

Thomas Vasicek

Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides. In exemplary embodiments, the satiation gut peptide pertains to PYY.

Satiation peptide administration

Pharmaceutical compositions comprising PYY (e.g., PYY(3-36) and analogs and variants thereof), satiety peptides, satiety hormones, metabolic hormones, and methods of treating metabolic diseases with such compositions are provided. Aspects include methods of increasing a feeling of fullness in patients treated with pharmaceutical compositions comprising PYY, PYY(3-36), satiety peptides, satiety hormones, metabolic hormones, and analogs, receptor antagonists and variants thereof.

Peptide YY pharmaceutical formulations, compositions, and methods

The present application provides methods and compositions for AAV-mediated delivery of PYY and Glucagon-like Peptide 1 or an analog thereof (e.g., Exendin-4) to a subject (e.g., the saliva of a subject). In some embodiments, compositions and methods for topical delivery of Ex-4 and PYY peptides also are provided. Methods and compositions are useful to promote weight loss and/or altered lipid taste sensitivity, as well as for the treatment of diabetes.

Satiation peptides for weight loss and altered taste sensitivity

Growing community of inventors

Rochester, MN, United States of America

Andres Acosta